PepGen Inc. has taken a significant step in its growth strategy by announcing a public offering of 25 million shares of its common stock. Priced at $5.00 per share, the offering is expected to raise approximately $116.9 million, which will primarily fund ongoing clinical development and support general corporate purposes.
The offering, which is set to close on or about November 13, 2026, is part of PepGen's strategy to enhance its financial resources as it continues to innovate within the pharmaceutical preparations sector. The company has granted underwriters a 30-day option to purchase an additional 3.75 million shares, potentially increasing the total proceeds to approximately $134.5 million.
Background
PepGen Inc., incorporated in Delaware, operates within the pharmaceutical preparations industry, identified by the Standard Industrial Classification (SIC) code 2834. The company trades under the ticker symbol PEPG on the Nasdaq exchange. As an emerging growth company, PepGen focuses on developing therapies that leverage its proprietary technology to treat various genetic diseases.
What the Filing Says
According to the recent SEC filing, "On November 11, 2026, PepGen Inc. entered into an underwriting agreement...pursuant to which the Company agreed to issue and sell an aggregate of 25,000,000 shares... at a price to the public of $5.00 per share." The filing also notes that the proceeds will be used for ongoing clinical development and other corporate purposes.
Impact
This offering is expected to positively impact PepGen's ability to fund its clinical trials and research initiatives. Additionally, it may influence other companies in the pharmaceutical preparations industry as they assess their own funding strategies in a competitive market.
What's Next
The offering is anticipated to close on or about November 13, 2026, pending the satisfaction of customary closing conditions. Further developments regarding the use of proceeds and clinical advancements are likely to follow in subsequent filings.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










